Researchers at U of T to study presence of COVID-19 antibodies in high- risk populations - News@UofT

The Canadian Partnership for Tomorrow’s Health (CanPath), hosted by the University of Toronto’s Dalla Lana School of Public Health, has received a $1.9 million investment from Canada’s COVID-19 Immunity Task Force to fund a study of COVID-19 seroprevalence across Canada.

“CanPath’s large number of participants, pan-Canadian reach, and population coverage enable us to detect differences in exposure and immunity among Canadians,” says Philip Awadalla, CanPath’s national scientific director and a professor in the department of molecular genetics in the Temerty Faculty of Medicine and at the Dalla Lana School of Public Health.

It is led by Awadalla and John McLaughlin, executive director of CanPath and a professor at the Dalla Lana School of Public Health.

As a result, these critical questions on immunity in the Canadian population can be addressed in an efficient and coordinated manner,” says Vivek Goel a member of the COVID-19 Immunity Task Force and a professor at the Dalla Lana School of Public Health’s Institute of Health Policy, Management and Evaluation.

The COVID-19 serology study builds upon a previous grant of more than $2.5 million awarded to CanPath by the Canadian Institutes of Health Research and the COVID-19 Immunity Task Force